Berg Pharma is classified as operating in the Research & Development in Biotechnology industry, NAICS Code 541711.
Trademark Applications
Trademark applications show the products and services that Berg Pharma is developing and marketing.
Berg Pharma doesn't have any recent trademark applications, indicating Berg Pharma is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
MAP Computer programs used in creating models of the proteome and biological systems of humans and animals for research and for diagnosis of human and animal disease states for medical and veterinary treatment
05/12/2010
EPIMETABOLICS Medical and veterinary testing, monitoring and reporting services for metabolic condition and detection and diagnosis of metabolic diseases
12/05/2008
EPIMETABOLOMICS Medical and veterinary testing, monitoring and reporting services for metabolic condition and detection and diagnosis of metabolic diseases
12/05/2008
See all trademarks and details in the Full Report.
Market Share of Berg Pharma's Largest Competitors
A competitive analysis shows these companies are in the same general field as Berg Pharma, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Berg Pharma.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Berg Pharma and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.